MIT just funded a program that's doing something quietly radical: taking brilliant lab scientists and helping them actually build companies around their discoveries.
The MIT-Royalty Pharma Faculty Founder Initiative launched in 2021 with a simple premise. Academic researchers often have breakthrough ideas that could save lives, but they're not entrepreneurs. They don't know how to raise money, build a team, or navigate the business side. So why not teach them.
The numbers tell the story. Over three years, 21 faculty members have gone through the two-year program. Sixteen of them have launched startups. Those startups have collectively raised over $70 million in seed funding. That's not theoretical impact — that's real companies with real funding, moving real treatments toward patients.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxHow does it work. Participants get workshops, mentorship from seasoned investors and founders, and executive education classes. But the real draw is the community. You're not doing this alone in your lab. You're surrounded by other scientists trying to become entrepreneurs, which turns out to matter.
Growing Beyond MIT
Royalty Pharma, a company that buys royalties from pharmaceutical products, committed $3 million to expand the program through 2029. The goal is ambitious: 40 faculty-founded life science ventures by 2029, up from the current 16.
The expansion just got real. The initiative announced its third cohort — 12 new members, six from MIT and six from the University of Oxford. This is the first time the program has gone international, bringing the model to one of the world's other major research hubs.
Why Oxford. The university has a thriving entrepreneurial ecosystem and deep expertise in biosensing technologies. Professor Molly Stevens, a world-leading expert in that field and herself an entrepreneur, is leading the Oxford side. The idea is that the same system that works at MIT can work elsewhere — and that two universities collaborating on this actually strengthens both.
The program's track record helps. Ellen Roche, a mechanical engineer at MIT, won the inaugural prize competition in 2021. Anne Carpenter, who runs the imaging platform at the Broad Institute, won in 2023. These aren't unknown researchers — they're accomplished scientists who might never have started companies without this structured support.
What's actually happening here is a shift in how breakthrough science reaches patients. Instead of waiting for a pharmaceutical company to license a discovery, faculty researchers can now shepherd their own ideas from lab to clinic. It's slower than a press release, but it's working.
